Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects

Interleukin-6 (IL-6) is a major survival factor for multiple myeloma (MM) cells preventing apoptosis induced by dexamethasone (DEX) or chemotherapy. 24 consecutive patients with MM in first-line therapy received DEX for 4 days, followed by melphalan (HDM: 140mg/m²) and autologous stem cell transplan...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Rossi, Jean-François, Fegueux, Nathalie, Lu, Zhao Yang, Legouffe, Eric, Exbrayat, Carole, Bozonnat, Marie-Cécile, Navarro, Robert, Lopez, Ernesto, Quittet, Philippe, Daures, Jean-Pierre, Rouillé, Valérie, Kanouni, Tarik, Widjenes, John, Klein, Bernard
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2005
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2034604/
https://ncbi.nlm.nih.gov/pubmed/16113665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bmt.1705138
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg